Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986189 Single Ascending Dose Study in Healthy Subjects
NCT02739373Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sepsis comparing BMS-986189 with Placebo (2 arms). Primary endpoints: Maximum observed concentration, Time of maximum observed concentration and 9 more. Started Apr 2016; status: completed.
02
Drugs
BMS-986189
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT02739373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02739373.